Answers are grounded in this paper and cite their sources.
Introduction The Aspergillus Galactomannan Antigen VirClia® Monotest (Vircell S.L., Granada, Spain) has been implemented in many laboratories in Spain; however, its use has not been clinically validated for the management of invasive pulmonary aspergillosis (IPA). Here, we gathered information on current practices related to the use of the VirClia® GM assay in Spanish hospitals. Methods Spanish laboratory users of the VirClia® assay were invited to respond to a standardized questionnaire. Results The questionnaire was completed in full by 35 out of 54 (64.8%) invited microbiology laboratories and by 14 clinicians. In addition to serum and bronchoalveolar lavages, non-validated sample types such as bronchoaspirates and endotracheal aspirates are used by around 20% of laboratories. Most laboratories (94.3%) report qualitative results using a threshold for positivity of >0.2, irrespective of the sample type and the patient's underlying condition, which is considered by most responding clinicians as a mycological criterion for probable IPA. Conclusion The current survey mainly reflects the heterogeneity in the use and interpretation of the VirClia® GM immunoassay, which, in the absence of clinically validated thresholds for probable IPA, introduces uncertainty and may lead to misinterpretations.
No takes yet. Share an insight, caveat, or question.
Medina et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: